What is the NOAEL for Climbazole?
Climbazole has 100 NOAEL studies in the database. The lowest reported value is 0.3 mg/m3 via inhalation in Human. Source: ToxValDB_GESTIS_DNEL.
NOAEL Data
REACH Registered
Cosmetic Ingredient
Climbazole
Also known as: 5-23-04-00209, Baypival, BRN 0618020, 1-(p-Chlorophenoxy)-3,3-dimethyl-1-(1-imidazolyl)-2-butanone, 1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutanone (+4 more)
CAS 38083-17-9
Climbazole (CAS 38083-17-9) is a chemical substance. Key regulatory status: REACH registered, 6 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, SCCS, ECHA REACH.
SOURCE
noael studies public
NOAEL studies
100
SOURCE
chemical inventory jurisdictions
Regulatory lists
6
SOURCE
eu clp annex vi
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
15 fields
Name
Climbazole
CAS Number
38083-17-9
DTXSID
DTXSID6046555
Molecular Formula
C15H17ClN2O2
InChI Key
OWEGWHBOCFMBLP-UHFFFAOYSA-N
Monoisotopic Mass
292.097855
Synonyms
5-23-04-00209BaypivalBRN 06180201-(p-Chlorophenoxy)-3,3-dimethyl-1-(1-imidazolyl)-2-butanone1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutanoneClimbazolEINECS 253-775-4ClimbazolumUNII-9N42CW7I54
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
9 records
BiocidePreservativeAnti-dandruff
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
6 records
| List | Keyword | Source |
|---|---|---|
| Europe; Personal care; restricted | European Commission | CosIng |
| Europe; Personal care | European Commission | CosIng |
| active_ingredient; Australia | Australian Pesticides and Veterinary Medicines Authority | CPCat |
| pharmaceutical | US International Trade Commission | CPCat |
| Europe; Personal care - hair styling and care - shampoo-dandruff | Danish Environmental Protection Agency | Danish EPA |
| Canada; pharmaceutical | DrugBank | DrugBank |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 50 of 100 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 5 | mg/kg bw/day | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 5 | mg/kg bw/day | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 5 | mg/kg bw/day | - | - | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 6 | - | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| =7.2 | mg/kg bw/day | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| =7.2 | mg/kg bw/day | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| =7.2 | mg/kg bw/day | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| =0.3 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB_GESTIS_DNEL |
| 9N42CW7I54 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 9N42CW7I54 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 9N42CW7I54 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 9N42CW7I54 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| =400 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =69.1 | mg/m3 | LOAEC | inhalation | Rat | ToxValDB_ECHA_IUCLID |
| 5 | mg/kg bw/day | LOAEL | oral | rat | COSMOS_DB |
| =50 | mg/kg bw/day | LOAEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =44.3 | mg/m3 | NOAEC | inhalation | Rat | ToxValDB_ECHA_IUCLID |
| =0.5 | % | NOAEL | oral | rat | SCCS_vision_codex |
| =0.5 | % | NOAEL | oral | rat | SCCS_vision_codex |
| =0.5 | % | NOAEL | oral | rat | SCCS_vision_codex |
| =0.5 | % | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg/day | NOAEL | oral | rat | SCCS_vision_codex |
| =5 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =6 | - | NOAEL | - | - | SCCS_vision_codex |
| =6 | - | NOAEL | - | - | SCCS_vision_codex |
| =6 | - | NOAEL | - | - | SCCS_vision_codex |
| =6 | - | NOAEL | - | - | SCCS_vision_codex |
| =7.2 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =7.2 | mg/kg | NOAEL | - | rat | SCCS_vision_codex |
| =7.2 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =7.2 | mg/kg | NOAEL | - | rat | SCCS_vision_codex |
| =7.2 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =7.2 | mg/kg | NOAEL | - | rat | SCCS_vision_codex |
| =7.2 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =7.2 | mg/kg | NOAEL | - | rat | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | - | dog | SCCS_vision_codex |
| =10 | mg/kg | NOAEL | - | rat | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | - | dog | SCCS_vision_codex |
| =10 | mg/kg | NOAEL | - | rat | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | - | dog | SCCS_vision_codex |
Showing 50 of 100 studies
REACH Registration
Registration status from the ECHA REACH registered substances database.
SOURCE
ECHA (EU)
1 records
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | Climbazole | 253-775-4 | ECHA overview → |
Australian Status (AICIS)
Australian industrial chemicals inventory status and applicable conditions.
SOURCE
AICIS inventory
1 records
Inventory Status
listed
SCCS Opinions
EU Scientific Committee opinions tied to the matched substance.
SOURCE
EU SCCS
6 opinions
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCS/1600/18 | 21-22 June 2018 | Safe with restrictions — safe as preservative in face cream/hair lotion/foot care at 0.2% and shampoo at 0.5%; not safe in body lotion | Preservative: 0.2% (face cream, hair lotion, foot care); 0.5% (rinse-off shampoo); Anti-dandruff: 2% (shampoo) | Aggregate exposure (multiple product use scenario); antifungal cross-resistance potential to medical azoles |
| SCCS/1590/17 | 24-25 October 2017 | Safe with restrictions — safe as anti-dandruff at 2% rinse-off and as preservative in face/hair/foot care at 0.2%; not safe in body lotion | Anti-dandruff: 2% (rinse-off); Preservative: 0.2% (leave-on face cream/hair lotion/foot care); 0.5% (rinse-off shampoo) | Aggregate exposure under combined use scenario |
| SCCS/1506/13 | 18 June 2013 | safe with restrictions | 0.5% in rinse-off hair products; 0.2% in face cream | Anti-fungal; potential endocrine effects; limited to specific product types and concentrations |
| SCCS/1500/12 | 18 June 2013 | Safe with restrictions — addendum confirming safety in face/hair/foot care at 0.2% and shampoo at 0.5% preservative; 2% anti-dandruff | Preservative: 0.2% (face cream/hair lotion/foot care); 0.5% (rinse-off shampoo); Anti-dandruff: 2% (shampoo) | Aggregate exposure when climbazole used simultaneously across product categories |
| SCCS/1498/12 | 26 February 2013 | Scientific opinion (not a safety conclusion) — addressed cross-resistance to medical azoles; no new safety limits set | N/A (cross-resistance assessment only) | Antifungal cross-resistance to azole medicinal products (itraconazole, fluconazole, etc.); concern for immunocompromised individuals |
| SCCP/0870/05 | 20 September 2005 | Insufficient data — comprehensive list of shortcomings in dossier; complete re-evaluation required | N/A (data insufficient for final conclusion) | Skin sensitization data inadequate; no acceptable in vitro dermal absorption study; incomplete mutagenicity/genotoxicity package; led to Submission II (SCCP/1204/08) |
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
restricted
Max
2.0% rinse-off (anti-dandruff) / 0.5% rinse-off (preservative) / 0.2% leave-on (preservative)
Category
active
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
EMBL-EBI ChEMBL
CLIMBAZOLE
ChEMBL Phase
2
Adverse Events
0
Bioactivity
4
Frequently Asked Questions
What regulatory lists include Climbazole?
Climbazole appears on 6 regulatory/inventory lists including Europe; Personal care; restricted, Europe; Personal care, active_ingredient; Australia, and 3 more. Source: EPA CPDat.
Is Climbazole used in cosmetics?
Yes, Climbazole is also indexed as a cosmetic ingredient under the name Climbazole. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for Climbazole come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Is Climbazole used outside industrial chemicals?
Climbazole also appears in cosmetics, pharmaceutical databases.